1. Home
  2. CYCN vs SNOA Comparison

CYCN vs SNOA Comparison

Compare CYCN & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyclerion Therapeutics Inc.

CYCN

Cyclerion Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$3.38

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCN
SNOA
Founded
2018
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
6.5M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
CYCN
SNOA
Price
$1.66
$3.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1M
17.4K
Earning Date
11-12-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,855,000.00
$16,937,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
1371.65
25.02
52 Week Low
$1.28
$1.75
52 Week High
$9.47
$6.92

Technical Indicators

Market Signals
Indicator
CYCN
SNOA
Relative Strength Index (RSI) 51.46 48.26
Support Level $1.48 $3.14
Resistance Level $1.60 $3.46
Average True Range (ATR) 0.09 0.23
MACD 0.05 0.01
Stochastic Oscillator 93.75 60.78

Price Performance

Historical Comparison
CYCN
SNOA

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: